BC Extra | Jan 4, 2020
Company News

Next act for BeiGene’s tislelizumab: a Leap deal for gastric cancer

Fresh off the approval of tislelizumab in China, BeiGene has partnered with Leap to pair the PD-1 inhibitor with the latter’s DKK1 inhibitor to create a combination therapy that could help treat cancers that don’t...
BC Extra | Aug 6, 2019
Clinical News

Leap zeroes in on subgroup for DKN-01, Keytruda combo

Shares of Leap tumbled Tuesday as investors digested updated data from the Phase I trial of DKN-01 that showed a lower response than reported in March for the mAb in combination with Keytruda for advanced...
BC Innovations | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
BC Week In Review | May 4, 2018
Clinical News

Leap reports Phase I data from DKN-01 plus Keytruda arm in esophageal cancer

Leap Therapeutics Inc. (NASDAQ:LPTX) reported data from seven evaluable patients with advanced esophagogastric cancer in the Phase I P102 trial showing that DKN-01 on days one and 15 of each 21-day cycle plus PD-1 inhibitor...
BC Week In Review | Apr 13, 2018
Clinical News

Leap reports Phase I data from monotherapy arm of esophageal cancer trial

Leap Therapeutics Inc. (NASDAQ:LPTX) reported data from 16 patients with advanced esophagogastric cancer in the Phase I P102 trial showing that DKN-01 as monotherapy led to two partial responses, plus five cases of stable disease....
BC Week In Review | Oct 24, 2016
Clinical News

DKN-01: Phase I data

Top-line data from a 2-part, open-label, U.S. Phase I trial in 27 patients with cholangiocarcinoma showed that 150 and 300 mg doses of IV DKN-01 plus gemcitabine and cisplatin on days 1 and 8 of...
BC Week In Review | Sep 5, 2016
Company News

Leap Therapeutics, Macrocure deal

Leap will merge with Macrocure in a deal that will create a publicly listed company with two clinical-stage immuno-oncology candidates. Leap’s DKN-01 , a mAb against dickkopf homolog 1 (DKK1) , is in Phase I/II testing for...
BC Extra | Aug 29, 2016
Company News

Leap merging with Macrocure

Leap Therapeutics Inc. (Cambridge, Mass.) is merging with Macrocure Ltd. (NASDAQ:MCUR) in a deal that will create a publicly listed company with two clinical-stage immuno-oncology candidates. Leap's DKN-01 , a mAb against dickkopf homolog 1 (DKK1),...
BC Week In Review | Aug 1, 2016
Clinical News

DKN-01: Additional Phase I data

Data from 22 evaluable patients with relapsed or refractory esophageal cancer in Parts A and B of the 4-part, open-label, dose-escalation Phase I P102 trial showed that twice-monthly DKN-01 plus once-weekly paclitaxel led to an...
BC Innovations | Feb 25, 2016
Distillery Therapeutics

Therapeutics: Dickkopf homolog 1 (DKK1)

Infectious disease INDICATION: Leishmaniasis; asthma Mouse studies suggest DKK1 inhibitors could help treat allergic asthma and cutaneous leishmaniasis. Blood levels of DKK1 were higher in a mouse model of dust mite allergen-induced asthma than in...
Items per page:
1 - 10 of 12